Synthesis and biological evaluation of sulfonamide analogues of the phosphatidylinositol 3-kinase inhibitor ZSTK474

被引：14
|
作者：
Gamage, Swarna A. [1 ]
Giddens, Anna C. [1 ]
Tsang, Kit Y. [1 ]
Flanagan, Jack U. [1 ,2 ]
Kendall, Jackie D. [1 ,2 ]
Lee, Woo-Jeong [3 ]
Baguley, Bruce C. [1 ,2 ]
Buchanan, Christina M. [2 ,3 ]
Jamieson, Stephen M. F. [1 ,2 ]
Shepherd, Peter R. [1 ,2 ,3 ]
Denny, William A. [1 ,2 ]
Rewcastle, Gordon W. [1 ,2 ]
机构：
[1] Univ Auckland, Fac Med & Hlth Sci, Auckland Canc Soc, Res Ctr, Private Bag 92019, Auckland 1142, New Zealand
[2] Univ Auckland, Maurice Wilkins Ctr Mol Biodiscovery, Private Bag 92019, Auckland 1142, New Zealand
[3] Univ Auckland, Fac Med & Hlth Sci, Dept Mol Med & Pathol, Private Bag 92019, Auckland 1142, New Zealand
来源：
BIOORGANIC & MEDICINAL CHEMISTRY | 2017年 / 25卷 / 20期
关键词：
Phosphatidylinositol; 3-kinase; PI3K; p110; alpha; ZSTK474; PHOSPHOINOSITIDE; 3-KINASE; CLASS-I; PI3K INHIBITOR; ISOFORM SELECTIVITY; BREAST-CANCER; PIK3CA GENE; DISCOVERY; PATHWAY; KINASE; MECHANISMS;
D O I：
10.1016/j.bmc.2017.09.025
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Replacement of one of the morpholine groups of the phosphatidylinositol 3-kinase (PI3K) inhibitor ZSTK474 (1) with sulfonamide containing substituents produced a new class of active and potent PI3K alpha inhibitors. Solubility issues prevented all but the 6-amino derivative 17 from being evaluated in vivo, but the clear activity of this compound demonstrated that this class of PI3K inhibitor shows great promise. (C) 2017 Elsevier Ltd. All rights reserved.
引用
收藏
页码：5859 / 5874
页数：16
相关论文
共 50 条
  • [21] Inhibitory effects of ZSTK474, a novel phosphoinositide 3-kinase inhibitor, on osteoclasts and collagen-induced arthritis in mice
    Shoko Toyama
    Naoto Tamura
    Kazuhiko Haruta
    Takeo Karakida
    Shigeyuki Mori
    Tetsuo Watanabe
    Takao Yamori
    Yoshinari Takasaki
    Arthritis Research & Therapy, 12
  • [22] Basal expression of insulin-like growth factor 1 receptor determines intrinsic resistance of cancer cells to a phosphatidylinositol 3-kinase inhibitor ZSTK474
    Isoyama, Sho
    Kajiwara, Gensei
    Tamaki, Naomi
    Okamura, Mutsumi
    Yoshimi, Hisashi
    Nakamura, Naoki
    Kawamura, Kento
    Nishimura, Yumiko
    Namatame, Nachi
    Yamori, Takao
    Dan, Shingo
    CANCER SCIENCE, 2015, 106 (02) : 171 - 178
  • [23] ZSTK474, a specific class I phosphatidylinositol 3-kinase inhibitor, induces G1 arrest and autophagy in human breast cancer MCF-7 cells
    Wang, Yaochen
    Liu, Jing
    Qiu, Yuling
    Jin, Meihua
    Chen, Xi
    Fan, Guanwei
    Wang, Ran
    Kong, Dexin
    ONCOTARGET, 2016, 7 (15) : 19897 - 19909
  • [24] Effectiveness of combined treatment using X-rays and a phosphoinositide 3-kinase inhibitor, ZSTK474, on proliferation of HeLa cells in vitro and in vivo
    Anzai, Kazunori
    Sekine-Suzuki, Emiko
    Ueno, Megumi
    Okamura, Mutsumi
    Yoshimi, Hisashi
    Dan, Shingo
    Yaguchi, Shin-ichi
    Enami, Jumpei
    Yamori, Takao
    Okayasu, Ryuichi
    CANCER SCIENCE, 2011, 102 (06) : 1176 - 1180
  • [25] Synthesis and Biological Evaluation of Novel Analogues of the Pan Class I Phosphatidylinositol 3-Kinase (PI3K) Inhibitor 2-(Difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474)
    Rewcastle, Gordon W.
    Gamage, Swarna A.
    Flanagan, Jack U.
    Frederick, Raphael
    Denny, William A.
    Baguley, Bruce C.
    Kestell, Philip
    Singh, Ripudaman
    Kendall, Jackie D.
    Marshall, Elaine S.
    Lill, Claire L.
    Lee, Woo-Jeong
    Kolekar, Sharada
    Buchanan, Christina M.
    Jamieson, Stephen M. F.
    Shepherd, Peter R.
    JOURNAL OF MEDICINAL CHEMISTRY, 2011, 54 (20) : 7105 - 7126
  • [26] Anti-angiogenic activity of a novel PI3K inhibitor, ZSTK474
    Kong, D.
    Yoshimi, H.
    Yamori, T.
    EJC SUPPLEMENTS, 2008, 6 (12): : 71 - 71
  • [27] ZSTK474, a novel anticancer drug candidate targeted at phosphatidylinositol-3 kinase: Identification of the molecular target using COMPARE analysis.
    Yamori, T
    Yaguchi, S
    Toshiyuki, M
    Fukui, Y
    Hirono, S
    Yamazaki, K
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9115S - 9115S
  • [28] In silico analysis of interaction between PI3K and its potent inhibitor ZSTK474
    Satoh, Hideki
    Koshimizu, Ichiro
    Yoshimi, Hisashi
    Watanabe, Tetsuo
    Yaguchi, Shin-ichi
    Matsuno, Toshiyuki
    Gouda, Hiroaki
    Yamori, Takao
    Hirono, Shuichi
    DRUGS OF THE FUTURE, 2007, 32 : 79 - 80
  • [29] The phosphoinositide 3-kinase inhibitor ZSTK474 increases the susceptibility of osteosarcoma cells to oncolytic vesicular stomatitis virus VSVΔ51 via aggravating endoplasmic reticulum stress
    Jiang, Jinqiong
    Wang, Weida
    Xiang, Weineng
    Jiang, Lin
    Zhou, Qian
    BIOENGINEERED, 2021, 12 (02) : 11847 - 11857
  • [30] Evaluation of antitumor activity of a novel PI3K inhibitor ZSTK474 by various human cancer xenograft models
    Yamori, T.
    Okamura, M.
    EJC SUPPLEMENTS, 2008, 6 (12): : 71 - 71
12345